Close Menu

NEW YORK (GenomeWeb) – Myriad Genetics today announced a companion diagnostic development pact with BeiGene, a company developing cancer treatments combining immunotherapy and molecularly targeted drugs.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.